Bullous pemphigoid
|
0.100 |
Biomarker
|
disease |
BEFREE |
Dipeptidyl peptidase-4 inhibitors and bullous pemphigoid: A systematic review and adjusted meta-analysis.
|
31215644 |
2020 |
Bullous pemphigoid
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Bullous pemphigoid associated with dipeptidyl peptidase-4 inhibitors. A case series and analysis of cases reported in the Spanish pharmacovigilance database.
|
31605541 |
2020 |
Bullous pemphigoid
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Bullous pemphigoid associated with dipeptidyl peptidase-4 inhibitor - A case report.
|
31535624 |
2020 |
Bullous pemphigoid
|
0.100 |
Biomarker
|
disease |
BEFREE |
There has been reported in a few case reports of increasing association between DPP-4 inhibitor use and bullous pemphigoid (BP).
|
31570343 |
2019 |
Bullous pemphigoid
|
0.100 |
Biomarker
|
disease |
BEFREE |
Dipeptidyl Peptidase-4 Inhibitor-Associated Bullous Pemphigoid.
|
31275298 |
2019 |
Bullous pemphigoid
|
0.100 |
Biomarker
|
disease |
BEFREE |
Heightened clinical vigilance for bullous pemphigoid associated with dipeptidyl peptidase-4 inhibitor use is required in daily diabetes care.
|
30989811 |
2019 |
Bullous pemphigoid
|
0.100 |
Biomarker
|
disease |
BEFREE |
The present study evaluated the relationship between BP and dipeptidyl peptidase-4 inhibitors (DPP4Is).
|
29920976 |
2019 |
Bullous pemphigoid
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Recently, the administration of dipeptidyl peptidase-IV inhibitors (DPP4i), which are widely used as antihyperglycemic drugs, has been recognized to be a causative factor for BP.
|
31191560 |
2019 |
Bullous pemphigoid
|
0.100 |
Biomarker
|
disease |
BEFREE |
Dipeptidyl peptidase-4 inhibitors have been suspected to induce bullous pemphigoid (BP).
|
30543900 |
2019 |
Bullous pemphigoid
|
0.100 |
Biomarker
|
disease |
BEFREE |
Meanwhile, use of DPP-4 inhibitors has been reported to be associated with the development of bullous pemphigoid (BP), a rare autoimmune blistering skin disease<sup>1</sup> , even though the absolute increase in the risk of development of BP is relatively low.
|
31774618 |
2019 |
Bullous pemphigoid
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Current use of DPP-4 inhibitors was associated with an increased risk of BP (47.3 vs. 20.0 per 100,000 person-years; HR 2.21 [95% CI 1.45-3.38]).
|
31182489 |
2019 |
Bullous pemphigoid
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
The association between use of DPP-4 inhibitors and risk of developing BP was analyzed using univariate and multivariate logistic regression analyses.
|
30624566 |
2019 |
Bullous pemphigoid
|
0.100 |
Biomarker
|
disease |
BEFREE |
A Cross-Sectional Study Comparing the Prevalence of Bullous Pemphigoid Autoantibodies in 275 Cases of Type II Diabetes Mellitus Treated With or Without Dipeptidyl Peptidase-IV Inhibitors.
|
31297116 |
2019 |
Bullous pemphigoid
|
0.100 |
Biomarker
|
disease |
BEFREE |
Linear regression analyses showed a considerable trend to significance for the linear correlation between the BP signal and gliptin affinity at DPP-4 (slope = 1.316 [-0.4385-3.21], p = 0.067, R<sup>2</sup> = 0.40) but not the other enzyme targets, nor for Vd.
|
31519110 |
2019 |
Bullous pemphigoid
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
To determine the effect of gliptins on the expression of the DPP-4/CD-26 protein we performed immunohistochemistry, which showed that the skin expression of DPP-4/CD-26 was increased in BP patients, but not affected by prior gliptin treatment.
|
30848289 |
2019 |
Bullous pemphigoid
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Various triggering factors are known to induce BP onset, including radiotherapy, burns, ultraviolet exposure, surgery, and the use of dipeptidyl peptidase-IV inhibitors (DPP4i), which are widely used antihyperglycemic drugs.
|
29706950 |
2018 |
Bullous pemphigoid
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Oral diabetes medications other than dipeptidyl peptidase 4 inhibitors are not associated with bullous pemphigoid: A Finnish nationwide case-control study.
|
29803903 |
2018 |
Bullous pemphigoid
|
0.100 |
Biomarker
|
disease |
BEFREE |
Our results showed that DPP-4 inhibitor-related BP has some distinct pathological characteristics from BP not associated with DPP-4 inhibitor.
|
29411416 |
2018 |
Bullous pemphigoid
|
0.100 |
Biomarker
|
disease |
BEFREE |
An association has been reported between BP and intake of gliptins, which are dipeptidyl peptidase-IV inhibitors used to treat type 2 diabetes mellitus.
|
29881377 |
2018 |
Bullous pemphigoid
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Recently, increasing numbers of BP cases which developed under the medication with dipeptidyl peptidase-4 inhibitors (DPP4i), widely used antihyperglycemic drugs, have been reported in published works.
|
29446164 |
2018 |
Bullous pemphigoid
|
0.100 |
Biomarker
|
disease |
BEFREE |
Overall, DPP-4 inhibitor intake was associated with a 3-fold increased risk for BP (adjusted odds ratio [OR], 3.2; 95% CI, 1.9-5.4).
|
30090931 |
2018 |
Bullous pemphigoid
|
0.100 |
Biomarker
|
disease |
BEFREE |
Withdrawal of DPP-4 inhibitors was effective in improving BP, and achieved remission even in cases requiring oral steroid administration and intravenous immunoglobulin therapy.
|
28520234 |
2018 |
Bullous pemphigoid
|
0.100 |
Biomarker
|
disease |
BEFREE |
Case reports have suggested an association between dipeptidyl peptidase-4 inhibitors (DPP4is) and development of bullous pemphigoid (BP).
|
29274348 |
2018 |
Bullous pemphigoid
|
0.100 |
Biomarker
|
disease |
BEFREE |
All patients diagnosed with DPP-4 inhibitor-associated bullous pemphigoid at dermatology departments in three Spanish centers during the period 2013 to 2015 were included.
|
29682739 |
2018 |